Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.13 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.13 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a cautious optimism regarding future developments. They are focused on advancing their product pipeline and exploring partnerships.
Management emphasized ongoing efforts in product development.
They highlighted the importance of upcoming milestones.
Focus remains on strategic partnerships to enhance growth.
The earnings report indicates that Soleno Therapeutics is still in a developmental phase, with no revenue reported. Despite missing EPS expectations, the stock rose by 1.46%, likely due to positive sentiment around future product developments and management's focus on strategic partnerships.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ADVANCE AUTO PTS INC
Nov 13, 2018